• Ticker

    Advertisement
DJIA 12,801.23 -89.23 -0.69%
NASDAQ 2,903.88 -23.35 -0.80%
S&P 500 1,342.64 -9.31 -0.69%
Maintenance Notification

Quotes and Portfolios will be down on Sunday February 12, 2012 from 2 AM to 4 AM while we perform maintenance on the site. We apologize for the inconvenience.

$1.01 -$0.04 (-3.37%)

Quote as of 4:00 PM EST on 02/10/12

Peregrine Pharmaceuticals

NASDAQ:PPHM

Jump to this page for:

Related Resources

Peregrine to Present at BIO CEO and Investor Conference on Tuesday, February 14, 2012 at 8:30 AM EST

2/9/2012 by Marketwire

Peregrine Pharmaceuticals management to meet with Roth Capital

1/27/2012 by Theflyonthewall.com

Peregrine Pharmaceuticals shares undervalued, says Roth Capital

1/23/2012 by Theflyonthewall.com

MissionIR News - Peregrine Pharmaceuticals (PPHM) Announces Preliminary Results for Phase II Hepatitis Study

12/30/2011 by PRWeb

Peregrine provides update on HCV clinical program

12/29/2011 by Theflyonthewall.com

Peregrine Provides Update on HCV Clinical Program

12/29/2011 by Marketwire

Peregrine Pharmaceuticals - Last quarter was truly remarkable for clinical pipeline

12/13/2011 by FutureSource.com

Peregrine Pharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript

12/12/2011 by Seeking Alpha

Peregrine Pharmaceuticals Inc. Reports Operating Results (10-Q)

12/12/2011 by GuruFocus

Peregrine Pharmaceuticals reports Q2 EPS (16c) vs. consensus (14c)

12/12/2011 by Theflyonthewall.com

Peregrine Pharmaceuticals Reports Second Quarter 2012 Financial Results and Recent Developments

12/12/2011 by Marketwire

Companies reporting After the Market Close on Monday, December 12

12/12/2011 by Theflyonthewall.com

Trading Radar for 12/12: Fuelcell Energy (FCEL), Avanir Pharma (AVNR), Peregrine Pharma (PPHM), Miller Energy (MILL) Report

12/9/2011 by StreetInsider.com

7 Reasons to Worry About Next Week

12/9/2011 by The Motley Fool

Avoid This Biotech Stock

12/7/2011 by The Motley Fool

Peregrine Pharmaceuticals, Inc.'s Bavituximab Shows 50% Improvement in Overall Tumor Response Rate in Randomized Phase II Lung Cancer Trial

12/6/2011 by BioSpace

Peregrine's Bavituximab shows 50% improvement in overall tumor response rate

12/6/2011 by Theflyonthewall.com

Peregrine's Bavituximab Shows 50% Improvement in Overall Tumor Response Rate in Randomized Phase II Lung Cancer Trial

12/6/2011 by Marketwire

Peregrine to Report Second Quarter Fiscal Year 2012 Financial Results After Market on December 12, 2011

12/5/2011 by Marketwire

Peregrine Pharma weakness creates buying opportunity, says Roth Capital

11/23/2011 by Theflyonthewall.com

Peregrine Pharmaceuticals, Inc. Reports Promising 23.2 Month Median Overall Survival From Phase II Advanced Breast Cancer Trial

11/22/2011 by BioSpace

Peregrine reports promising 23.2 month median survival for phase 2 trial

11/22/2011 by Theflyonthewall.com

Peregrine Reports Promising 23.2 Month Median Overall Survival From Phase II Advanced Breast Cancer Trial

11/22/2011 by Marketwire

Peregrine to Present at Lazard Healthcare Conference November 15, 2011 at 11:30 AM EST

11/8/2011 by Marketwire

5 Stocks Poised for Breakouts

11/7/2011 by TheStreet.com

Peregrine Pharmaceuticals management to meet with JMP Securities

10/20/2011 by Theflyonthewall.com

A Peek At Peregrine Pharma

10/20/2011 by RTTNews

SIRO Clinpharm and Peregrine Pharmaceuticals Highlight Successful Collaboration

10/11/2011 by PR Newswire

Peregrine Pharmaceuticals - MLV Capital on Bavi program

10/7/2011 by FutureSource.com

Peregrine Completes Patient Enrollment in Second-Line Non-Small Cell Lung Cancer Trial; Data to Be Unblinded in First Half 2012

10/6/2011 by Marketwire

Peregrine Pharmaceuticals completes enrollement in Phase II Bavituximab trial

9/26/2011 by Theflyonthewall.com

Peregrine Completes Patient Enrollment in Randomized Phase II HCV Trial for Bavituximab

9/26/2011 by Marketwire

Peregrine to Present at JMP Securities Healthcare Conference September 27, 2011 at 12:00 PM EDT

9/20/2011 by Marketwire

Peregrine Pharma (PPHM) Presents Strong Data from PS-Targeting Tumor Studies

9/12/2011 by StreetInsider.com

Peregrine PS-Targeting Antibodies Show Broad Potential to Image Tumors and Assess Cancer Therapy Response

9/12/2011 by Marketwire

Peregrine Pharmaceuticals Inc. Reports Operating Results (10-Q)

9/9/2011 by GuruFocus

Peregrine Pharmaceuticals' CEO Discusses Q1 2012 Results - Earnings Call Transcript

9/9/2011 by Seeking Alpha

Peregrine Pharmaceuticals, Inc. (PPHM) Posts Narrower than Expected Q1 Loss

9/9/2011 by StreetInsider.com

Peregrine Pharmaceuticals reports Q1 EPS (11c) vs. consensus (15c)

9/9/2011 by Theflyonthewall.com

Peregrine Pharmaceuticals Reports First Quarter Fiscal Year 2012 Financial Results and Recent Developments

9/9/2011 by Marketwire
See More Articles...